Intelligence for Neurology Specialists

Neurology clinical trials
recruiting in the United States

Up-to-date overview of clinical trials in Parkinson's disease, Alzheimer's, dementia, epilepsy, multiple sclerosis and other neurological conditions recruiting patients in the United States β€” automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centers.

112
Active trials
1037
US sites
52
Indications covered
41
BR trials
Loading map…
Loading map…

112 studies found

N/DTumores do Sistema Nervoso CentralTumores de Nervos PerifericosEpilepsiaUS 1 site in the US

Evaluation and Treatment of Neurosurgical Disorders

National Institute of Neurological Disorders and Stroke (NINDS)

πŸ“ BethesdaπŸ‘₯ 5000 participants
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1, Fase 2Multiple SclerosisAlzheimerUS 1 site in the US

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Brigham and Women's Hospital

πŸ“ BostonπŸ‘₯ 250 participantsπŸ“… Completion: 2027-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1Falha Autonomica PuraAtrofia de Multiplos SistemasDoenca de ParkinsonUS 1 site in the US

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

Vanderbilt University Medical Center

πŸ“ NashvilleπŸ‘₯ 34 participantsπŸ“… Completion: 2026-09
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DEnvelhecimento NormalDoenca de ParkinsonUS 2 sites in the US

Pilot Intervention With Near Infrared Stimulation

University of Florida

πŸ“ Gainesville, TucsonπŸ‘₯ 24 participantsπŸ“… Completion: 2026-04
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Cancer de ProstataUS 1 site in the US

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Mark Garzotto, MD

πŸ“ PortlandπŸ‘₯ 32 participantsπŸ“… Completion: 2022-09
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 4Alzheimer DiseaseUS 1 site in the US

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

Mayo Clinic

πŸ“ JacksonvilleπŸ‘₯ 614 participantsπŸ“… Completion: 2030-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DSleep Dependent LearningUS 1 site in the US

Sleep-dependent Learning in Aging

University of Massachusetts, Amherst

πŸ“ AmherstπŸ‘₯ 584 participantsπŸ“… Completion: 2025-07
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Age Related Cognitive DeclineAlzheimer Disease And Related DementiasUS 4 sites in the US

Preventing Alzheimer's With Cognitive Training

University of South Florida

πŸ“ Durham, Sarasota, Seneca, TampaπŸ‘₯ 7600 participantsπŸ“… Completion: 2026-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Alzheimer DiseaseComprometimento CognitivoDeclinio CognitivoUS 1 site in the US

Biomarker Exploration in Aging, Cognition and Neurodegeneration

University of California, Irvine

πŸ“ IrvineπŸ‘₯ 300 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinson DiseaseUS 1 site in the US

Globus Pallidus Stimulation to Treat Insomnia

Mayo Clinic

πŸ“ JacksonvilleπŸ‘₯ 10 participantsπŸ“… Completion: 2029-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DPerda Auditiva SensorioneuralDemencia de AlzheimerComprometimento Cognitivo Leve AmnesticoUS 2 sites in the US

Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia

Northwestern University

πŸ“ Chicago, EvanstonπŸ‘₯ 20 participantsπŸ“… Completion: 2027-08
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1Falha Autonomica PuraDoenca de ParkinsonAtrofia de Multiplos SistemasUS 1 site in the US

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Daniel Claassen

πŸ“ NashvilleπŸ‘₯ 40 participantsπŸ“… Completion: 2027-02
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1, Fase 2Autoimmune DiseasesCardiovascular DisordersDiabetes ComplicationsUS 1 site in the US

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

Thomas Advanced Medical LLC

πŸ“ Culver CityπŸ‘₯ 5000 participantsπŸ“… Completion: 2030-07
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinsons DiseaseTremor EssencialDistoniaUS 1 site in the US

Investigating Inhibitory Control Networks in Parkinson's Disease

University of Alabama at Birmingham

πŸ“ BirminghamπŸ‘₯ 140 participantsπŸ“… Completion: 2027-03
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1Alzheimer DiseaseUS 1 site in the US

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Baylor College of Medicine

πŸ“ HoustonπŸ‘₯ 52 participantsπŸ“… Completion: 2026-04
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 4Major Depressive DisorderAlzheimer DiseaseUS 2 sites in the US

AΞ² Dynamics in LLMD

NYU Langone Health

πŸ“ New York, OrangeburgπŸ‘₯ 60 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1Non Small Cell Lung CancerUS 5 sites in the US

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

BioNTech SE

πŸ“ Baltimore, Fairfax, Houston, Lexington, LouisvilleπŸ‘₯ 320 participantsπŸ“… Completion: 2030-02
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Doenca de ParkinsonUS 3 sites in the US

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

Gateway Institute for Brain Research

πŸ“ Davie, Hialeah, MiamiπŸ‘₯ 56 participantsπŸ“… Completion: 2027-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 4Parkinson DiseaseParkinson Disease PsychosisDemencia de Corpos de LewyUS 1 site in the US

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Vanderbilt University Medical Center

πŸ“ NashvilleπŸ‘₯ 75 participantsπŸ“… Completion: 2026-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1, Fase 2Amyotrophic Lateral SclerosisAlzheimer DiseaseMultiple SclerosisUS 3 sites in the US

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Ashvattha Therapeutics, Inc.

πŸ“ Jacksonville, San Francisco, StanfordπŸ‘₯ 65 participantsπŸ“… Completion: 2026-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DDoenca de ParkinsonHipotensao OrtostaticaDisautonomiaUS 1 site in the US

Blood Pressure Effects on Cognition and Brain Blood Flow in PD

University of California, San Diego

πŸ“ San DiegoπŸ‘₯ 60 participantsπŸ“… Completion: 2026-08
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DDepressionUS 1 site in the US

Depression and Driving

Washington University School of Medicine

πŸ“ St LouisπŸ‘₯ 150 participantsπŸ“… Completion: 2027-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinsons DiseaseUS 1 site in the US

Udall Project 1 Aim 4

University of Minnesota

πŸ“ MinneapolisπŸ‘₯ 100 participantsπŸ“… Completion: 2027-03
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer Disease Early OnsetUS 1 site in the US

Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study

Indiana University

πŸ“ IndianapolisπŸ‘₯ 60 participantsπŸ“… Completion: 2028-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAgingAlzheimer DiseaseUS 1 site in the US

The Role of the Locus Coeruleus in Age-related Distractibility

Virginia Polytechnic Institute and State University

πŸ“ BlacksburgπŸ‘₯ 200 participantsπŸ“… Completion: 2027-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseUS 1 site in the US

Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease

Rhode Island Hospital

πŸ“ ProvidenceπŸ‘₯ 40 participantsπŸ“… Completion: 2024-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimers DiseaseUS 2 sites in the US

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

University of Pennsylvania

πŸ“ Boston, PhiladelphiaπŸ‘₯ 100 participantsπŸ“… Completion: 2027-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DMinorias Sexuais e de GeneroHospice Cuidados PaliativosAlzheimer e Demencias RelacionadasUS 1 site in the US

Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice

University of Colorado, Denver

πŸ“ AuroraπŸ‘₯ 80 participantsπŸ“… Completion: 2027-09
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1Parkinson DiseaseUS 1 site in the US

Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder

University of Minnesota

πŸ“ MinneapolisπŸ‘₯ 60 participantsπŸ“… Completion: 2029-07
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DDeliriumMild Cognitive ImpairmentAlzheimer DiseaseUS 7 sites in the US

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

University of Michigan

πŸ“ Ann Arbor, Madison, Orange, Philadelphia, Pittsburgh, Portland, Salt Lake CityπŸ‘₯ 1900 participantsπŸ“… Completion: 2027-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DSedentarismo e Inatividade FisicaObesidadeUS 1 site in the US

Goal Setting to Promote Physical Activity Adherence in Midlife Adults

Arizona State University

πŸ“ PhoenixπŸ‘₯ 144 participantsπŸ“… Completion: 2027-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseUS 1 site in the US

Gamma-Music Based Intervention for Mild Alzheimer's Disease

Northeastern University

πŸ“ BostonπŸ‘₯ 60 participantsπŸ“… Completion: 2027-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2OsteoporosisUS 1 site in the US

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

Duke University

πŸ“ DurhamπŸ‘₯ 45 participantsπŸ“… Completion: 2026-11
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Alzheimer DiseaseUS 1 site in the US

Phase II Clinical Trial of Interleukin-2 in AD

The Methodist Hospital Research Institute

πŸ“ HoustonπŸ‘₯ 40 participantsπŸ“… Completion: 2025-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1Parkinsons DiseaseMultiple System AtrophyDementia With Lewy BodiesUS 1 site in the US

PET Imaging Evaluation of [11C]SY08

Massachusetts General Hospital

πŸ“ CharlestownπŸ‘₯ 40 participantsπŸ“… Completion: 2026-11
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DMild Cognitive ImpairmentAlzheimer Disease And Related DementiasPerda AuditivaUS 2 sites in the US

OTC Hearing Aid and MCI

Northwestern University

πŸ“ Evanston, MadisonπŸ‘₯ 50 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseUS 1 site in the US

Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1

Washington University School of Medicine

πŸ“ St LouisπŸ‘₯ 80 participantsπŸ“… Completion: 2027-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinson DiseaseUS 1 site in the US

Unlocking Movement Potential: Enhancing Parkinson's Disease Treatment With Robotic EksoSkeleton

Albert Einstein Healthcare Network

πŸ“ Elkins ParkπŸ‘₯ 24 participantsπŸ“… Completion: 2026-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer Disease And Related DementiasCancerUS 1 site in the US

Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision

University of Rochester

πŸ“ RochesterπŸ‘₯ 300 participantsπŸ“… Completion: 2027-04
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1Alzheimer DiseaseAlzheimer Dominante Autossomico Psen1Alzheimer Dominante Autossomico Psen2US 1 site in the US

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

University College, London

πŸ“ St LouisπŸ‘₯ 10 participantsπŸ“… Completion: 2026-07
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParagangliomaFeocromocitomaEsclerose Lateral AmiotroficaUS 1 site in the US

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

University of Pennsylvania

πŸ“ PhiladelphiaπŸ‘₯ 1000 participantsπŸ“… Completion: 2027-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DComprometimento Cognitivo LeveDoenca de AlzheimerUS 1 site in the US

Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

NeuroVision Imaging

πŸ“ SacramentoπŸ‘₯ 200 participantsπŸ“… Completion: 2026-04
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DCritical IllnessDeliriumComprometimento CognitivoUS 1 site in the US

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

University of Washington

πŸ“ SeattleπŸ‘₯ 100 participantsπŸ“… Completion: 2027-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseUS 1 site in the US

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

Washington University School of Medicine

πŸ“ St LouisπŸ‘₯ 60 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinson DiseaseUS 1 site in the US

Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial

Jay Alberts

πŸ“ ClevelandπŸ‘₯ 200 participantsπŸ“… Completion: 2028-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Parkinsons DiseaseDepressaoUS 1 site in the US

Psilocybin Therapy for Depression in Parkinson's Disease

Joshua Woolley, MD, PhD

πŸ“ San FranciscoπŸ‘₯ 60 participantsπŸ“… Completion: 2027-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinson DiseaseUS 1 site in the US

Action Regulation Behavioral

University of Texas Southwestern Medical Center

πŸ“ DallasπŸ‘₯ 50 participantsπŸ“… Completion: 2026-11
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinsons DiseaseUS 1 site in the US

Blood Flow Restriction for Optimizing Balance in Parkinson's Disease

The University of Texas Health Science Center at San Antonio

πŸ“ San AntonioπŸ‘₯ 20 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1Comprometimento Cognitivo LeveAlzheimerUS 1 site in the US

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

University of California, San Diego

πŸ“ San DiegoπŸ‘₯ 60 participantsπŸ“… Completion: 2027-04
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinson DiseaseUS 1 site in the US

Home-Based Monitoring in Parkinson's Disease

Jacob E. Simmering

πŸ“ Iowa CityπŸ‘₯ 120 participantsπŸ“… Completion: 2027-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2StrokeParkinson DiseaseDisfagiaUS 1 site in the US

Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

Purdue University

πŸ“ West LafayetteπŸ‘₯ 120 participantsπŸ“… Completion: 2028-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Parkinson DiseaseUS 1 site in the US

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Vikas Kotagal

πŸ“ Ann ArborπŸ‘₯ 102 participantsπŸ“… Completion: 2029-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Doenca de ParkinsonUS 45 sites in the US

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Neuron23 Inc.

πŸ“ Albuquerque, Atlanta, Augusta, Aurora, Baltimore, Boca Raton, Boston, Chapel HillπŸ‘₯ 150 participantsπŸ“… Completion: 2027-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinson DiseaseUS 1 site in the US

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

University of Minnesota

πŸ“ MinneapolisπŸ‘₯ 25 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseComprometimento Cognitivo LeveDemenciaUS 1 site in the US

ADRC Clinical Cohort (Alzheimer's Disease)

Duke University

πŸ“ DurhamπŸ‘₯ 500 participantsπŸ“… Completion: 2026-08
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseUS 1 site in the US

Testing the Effects of a Text Message Caregiver Support Intervention for Latinos

University of Kansas Medical Center

πŸ“ FairwayπŸ‘₯ 288 participantsπŸ“… Completion: 2029-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1, Fase 2Parkinsons DiseaseUS 2 sites in the US

A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

Sumitomo Pharma America, Inc.

πŸ“ Lexington, New YorkπŸ‘₯ 25 participantsπŸ“… Completion: 2030-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 4Parkinsons DiseaseUS 23 sites in the US

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Impax Laboratories, LLC

πŸ“ Aliso Viejo, Aventura, Boca Raton, Canton, Cincinnati, Cleveland, Commack, DallasπŸ‘₯ 220 participantsπŸ“… Completion: 2025-11
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DMild Cognitive ImpairmentAlzheimer DementiaTraumatic Brain InjuryUS 1 site in the US

Mindfulness for Cognition in Early-stage Alzheimer's Disease

VA Boston Healthcare System

πŸ“ BostonπŸ‘₯ 100 participantsπŸ“… Completion: 2027-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1Parkinson DiseaseUS 9 sites in the US

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Eli Lilly and Company

πŸ“ Austin, Farmington Hills, Los Alamitos, Naples, Orlando, Port Orange, The VillagesπŸ‘₯ 127 participantsπŸ“… Completion: 2028-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseDemenciaUS 1 site in the US

Connect-Home: Alzheimer's Disease and Related Dementias

University of North Carolina, Chapel Hill

πŸ“ Chapel HillπŸ‘₯ 360 participantsπŸ“… Completion: 2027-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinson DiseaseUS 1 site in the US

Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease

St. Louis University

πŸ“ St LouisπŸ‘₯ 40 participantsπŸ“… Completion: 2027-03
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinson DiseaseEssential TremorUS 1 site in the US

Attention and Eye Movement in Parkinson's Disease

University of Nebraska

πŸ“ OmahaπŸ‘₯ 138 participantsπŸ“… Completion: 2028-02
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseDemenciaPerda AuditivaUS 1 site in the US

HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

Johns Hopkins University

πŸ“ BaltimoreπŸ‘₯ 300 participantsπŸ“… Completion: 2027-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Alzheimer DiseaseAgitacao em AlzheimerAgitacao em DemenciaUS 10 sites in the US

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Bristol-Myers Squibb

πŸ“ Bountiful, Carrollton, Las Vegas, Miami, Morehead City, Newton, Port Orange, ScottsdaleπŸ‘₯ 650 participantsπŸ“… Completion: 2029-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Parkinsons DiseaseUS 33 sites in the US

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

BlueRock Therapeutics

πŸ“ Ann Arbor, Aurora, Baltimore, Boston, Buffalo, Burlington, Charleston, ChicagoπŸ‘₯ 102 participantsπŸ“… Completion: 2027-03
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2, Fase 3Parkinson DiseaseUS 15 sites in the US

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Biohaven Therapeutics Ltd.

πŸ“ Atlantis, Bellevue, Birmingham, Boca Raton, Boston, Chesterfield, Chicago, FarmingtonπŸ‘₯ 550 participantsπŸ“… Completion: 2027-08
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DDor CronicaDepressaoAnsiedadeUS 1 site in the US

Just-In-Time Adaptive Interventions (JITAIs) in a Digital Mental Health Intervention for Middle-Aged and Older Adults With Chronic Pain

Washington University School of Medicine

πŸ“ St LouisπŸ‘₯ 1000 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Cancer de EndometrioEndometrial CancerUS 36 sites in the US

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

AstraZeneca

πŸ“ Ann Arbor, Arlington Heights, Augusta, Austin, Baltimore, Boston, Charleston, CharlotteπŸ‘₯ 600 participantsπŸ“… Completion: 2029-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinsons DiseaseUS 1 site in the US

Imaging Core Aim 2, and Udall Project 2 Aim 2

University of Minnesota

πŸ“ MinneapolisπŸ‘₯ 20 participantsπŸ“… Completion: 2027-07
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinsons Disease IdiopaticaUS 1 site in the US

The Impact of Deep Brain Stimulation on Speech and Swallow Function in Parkinson Disease

University of Florida

πŸ“ GainesvilleπŸ‘₯ 100 participantsπŸ“… Completion: 2028-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DEnvelhecimentoUS 1 site in the US

Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging

National Institute on Aging (NIA)

πŸ“ BaltimoreπŸ‘₯ 400 participantsπŸ“… Completion: 2029-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1, Fase 2Parkinson Disease Com Comprometimento Cognitivo LeveDemencia da Doenca de ParkinsonUS 1 site in the US

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

Prabesh Kanel

πŸ“ Ann ArborπŸ‘₯ 45 participantsπŸ“… Completion: 2027-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Alzheimers DiseaseUS 33 sites in the US

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Hoffmann-La Roche

πŸ“ Albuquerque, Arlington, Atlantis, Beaumont, Boston, Chicago, Clermont, DallasπŸ‘₯ 800 participantsπŸ“… Completion: 2028-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DMild Cognitive ImpairmentMild Alzheimer DiseaseUS 1 site in the US

A Study To Assess The Feasibility Of Indivi Mobile Application In Monitoring Cognitive Performance In Aging Population

Indivi AG

πŸ“ BostonπŸ‘₯ 55 participantsπŸ“… Completion: 2026-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Alzheimers DiseaseUS 68 sites in the US

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Hoffmann-La Roche

πŸ“ Albuquerque, Arlington, Atlanta, Atlantis, Beaumont, Birmingham, Boston, BrownsvilleπŸ‘₯ 13000 participantsπŸ“… Completion: 2035-07
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinsons DiseaseParkinsons Disease DementiaAlzheimers DiseaseUS 2 sites in the US

Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease

Sanmai Technologies PBC dba Sanmai

πŸ“ New York, Santa MonicaπŸ‘₯ 60 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DDoenca de ParkinsonControle SaudavelUS 1 site in the US

Effects of Vagal Nerve Stimulation on Leg Muscle Activity and Posture in Parkinson's Disease

University of Minnesota

πŸ“ MinneapolisπŸ‘₯ 75 participantsπŸ“… Completion: 2029-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Alzheimer DiseaseUS 1 site in the US

Open-Label Extension Protocol to SNK01-AD01 Study

NKGen Biotech, Inc.

πŸ“ GlendaleπŸ‘₯ 30 participantsπŸ“… Completion: 2028-04
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseOutras DemenciasUS 1 site in the US

Remote tDCS and Chair Yoga for Chronic Knee Pain in Alzheimer's Patients

University of Arizona

πŸ“ TucsonπŸ‘₯ 40 participantsπŸ“… Completion: 2026-08
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinsons DiseaseUS 1 site in the US

Electrophysiology-based DBS Programming for PD

University of Florida

πŸ“ GainesvilleπŸ‘₯ 30 participantsπŸ“… Completion: 2027-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DDoenca de ParkinsonUS 1 site in the US

Low Versus High Load Training and Parkinson's Disease

University of Miami

πŸ“ Coral GablesπŸ‘₯ 60 participantsπŸ“… Completion: 2027-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinsons DiseaseUS 1 site in the US

Speech Learning and Speech Production in Parkinson's Disease

State University of New York at Buffalo

πŸ“ BuffaloπŸ‘₯ 50 participantsπŸ“… Completion: 2027-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DDemenciaAlzheimerEstresse do CuidadorUS 1 site in the US

Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers

Virginia Wesleyan University

πŸ“ Virginia BeachπŸ‘₯ 65 participantsπŸ“… Completion: 2026-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DEssential TremorEssential Tremor PlusUS 2 sites in the US

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

CND Life Sciences

πŸ“ Memphis, ScottsdaleπŸ‘₯ 300 participantsπŸ“… Completion: 2027-02
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Psicose Associada ao AlzheimerUS 3 sites in the US

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

MapLight Therapeutics

πŸ“ Doral, MiamiπŸ‘₯ 210 participantsπŸ“… Completion: 2029-03
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DAlzheimer DiseaseUS 7 sites in the US

Dominantly Inherited Alzheimer Network (DIAN)

Washington University School of Medicine

πŸ“ Boston, Indianapolis, Jacksonville, Pittsburgh, Providence, Seattle, St LouisπŸ‘₯ 700 participantsπŸ“… Completion: 2027-07
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1, Fase 2Esophageal Squamous Cell CarcinomaUS 4 sites in the US

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Merck Sharp & Dohme LLC

πŸ“ East Syracuse, Los Angeles, Pittsburgh, TucsonπŸ‘₯ 230 participantsπŸ“… Completion: 2027-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Psicose Associada a Doenca de AlzheimerUS 57 sites in the US

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

πŸ“ Anaheim, Atlanta, Bonita Springs, Clermont, Cutler Bay, Cypress, Daytona Beach, DoralπŸ‘₯ 1000 participantsπŸ“… Completion: 2027-09
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2, Fase 3Alzheimer Disease PsychosisUS 29 sites in the US

ACP-204 in Adults With Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals Inc.

πŸ“ Abington, Aventura, Chandler, Costa Mesa, Cypress, Daytona Beach, Doral, FresnoπŸ‘₯ 1074 participantsπŸ“… Completion: 2028-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Non Small Cell Lung CancerUS 10 sites in the US

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) β‰₯ 50% (MK-2870-007)

Merck Sharp & Dohme LLC

πŸ“ Burbank, Corvallis, Grand Junction, Hattiesburg, Jacksonville, Minneapolis, Phoenix, RenoπŸ‘₯ 614 participantsπŸ“… Completion: 2028-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3hr Positive Her2 Negative Breast CancerUS 42 sites in the US

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Merck Sharp & Dohme LLC

πŸ“ Altamonte Springs, Aurora, Baltimore, Baton Rouge, Boston, Brooklyn, Chandler, CharlotteπŸ‘₯ 1200 participantsπŸ“… Completion: 2027-07
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Non Small Cell Lung CancerUS 13 sites in the US

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) β‰₯50% (MK-1084-004/KANDLELIT-004)

Merck Sharp & Dohme LLC

πŸ“ Albany, Bakersfield, Beverly Hills, Billings, Cincinnati, Houston, Kansas City, LancasterπŸ‘₯ 600 participantsπŸ“… Completion: 2029-02
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1, Fase 2Adenocarcinoma GastricoAdenocarcinoma da Juncao GastroesofagicaAdenocarcinoma EsofagicoUS 6 sites in the US

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Merck Sharp & Dohme LLC

πŸ“ East Syracuse, Grand Rapids, Houston, Los Angeles, Pittsburgh, TucsonπŸ‘₯ 210 participantsπŸ“… Completion: 2028-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 1, Fase 2Adenocarcinoma GastroesofagicoCancer EsofagicoUS 6 sites in the US

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Merck Sharp & Dohme LLC

πŸ“ East Syracuse, Grand Rapids, Houston, Los Angeles, Pittsburgh, TucsonπŸ‘₯ 160 participantsπŸ“… Completion: 2029-09
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Transthyretin AmyloidosisAmyloid CardiomyopathyHereditary Transthyretin PolyneuropathyUS 39 sites in the US

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Eidos Therapeutics, a BridgeBio company

πŸ“ Atlanta, Aurora, Austin, Baltimore, Boston, Charleston, Chicago, ClevelandπŸ‘₯ 587 participantsπŸ“… Completion: 2031-10
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Alzheimer DiseaseUS 39 sites in the US

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

πŸ“ Anaheim, Atlanta, Bellevue, Belmont, Bloomfield Township, Bonita Springs, Boston, ChinoπŸ‘₯ 406 participantsπŸ“… Completion: 2026-11
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Non Small Cell Lung CancerUS 48 sites in the US

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Merck Sharp & Dohme LLC

πŸ“ Aurora, Bethlehem, Boston, Buffalo, Charlotte, Chattanooga, Chicago, CincinnatiπŸ‘₯ 680 participantsπŸ“… Completion: 2033-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Esclerose Sistemica Difusa CutaneaUS 14 sites in the US

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Novartis Pharmaceuticals

πŸ“ Ann Arbor, Boston, Chicago, Columbus, Iowa City, Los Angeles, Minneapolis, PortlandπŸ‘₯ 96 participantsπŸ“… Completion: 2028-11
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Dravet SyndromeUS 21 sites in the US

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Longboard Pharmaceuticals

πŸ“ Aurora, Austin, Bethesda, Chicago, Fort Worth, Gulf Breeze, Houston, Little RockπŸ‘₯ 160 participantsπŸ“… Completion: 2026-08
View details β†’Refer patient β†’ClinicalTrials.gov β†—
N/DParkinson DiseaseUS 2 sites in the US

TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD

Oregon Health and Science University

πŸ“ Portland, TempeπŸ‘₯ 60 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Cancer de Mama Triplo NegativoUS 37 sites in the US

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Merck Sharp & Dohme LLC

πŸ“ Albuquerque, Altamonte Springs, Athens, Baltimore, Boise, Chandler, Chicago, ClintonπŸ‘₯ 1000 participantsπŸ“… Completion: 2030-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Endometrial CancerUS 43 sites in the US

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Merck Sharp & Dohme LLC

πŸ“ Albuquerque, Anchorage, Bethlehem, Boston, Centerville, Chicago, Columbus, CovingtonπŸ‘₯ 1123 participantsπŸ“… Completion: 2032-05
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Triple Negative Breast Cancerhr Low Positive Her2 Negative Breast CancerUS 59 sites in the US

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme LLC

πŸ“ Abilene, Altamonte Springs, Baltimore, Burbank, Charleston, Cincinnati, Clovis, DallasπŸ‘₯ 2400 participantsπŸ“… Completion: 2033-03
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Alzheimer DiseaseUS 24 sites in the US

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Bristol-Myers Squibb

πŸ“ Albany, Amherst, Buffalo, Chicago, Colorado Springs, Farmington Hills, Fort Myers, FullertonπŸ‘₯ 586 participantsπŸ“… Completion: 2028-09
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Alzheimer DiseaseUS 25 sites in the US

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Bristol-Myers Squibb

πŸ“ Atlantis, Aventura, Basalt, Beaumont, Chicago, Columbus, Cordova, DaytonπŸ‘₯ 586 participantsπŸ“… Completion: 2028-09
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Encefalopatia do Desenvolvimento e EpilepticaUS 6 sites in the US

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

Praxis Precision Medicines

πŸ“ Chevy Chase, Gulf Breeze, Hackensack, La Jolla, Philadelphia, RosevilleπŸ‘₯ 160 participantsπŸ“… Completion: 2026-12
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Alzheimer DiseaseUS 22 sites in the US

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Bristol-Myers Squibb

πŸ“ Anaheim, Bennington, Bloomfield Hills, El Paso, Gaithersburg, Las Vegas, Miami, New WindsorπŸ‘₯ 426 participantsπŸ“… Completion: 2028-11
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 2Multiple SclerosisUS 9 sites in the US

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Hoffmann-La Roche

πŸ“ Baltimore, Carlsbad, Fort Collins, Knoxville, Maitland, Seattle, Syracuse, TampaπŸ‘₯ 182 participantsπŸ“… Completion: 2027-01
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Alzheimers DiseaseUS 35 sites in the US

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Hoffmann-La Roche

πŸ“ Birmingham, Boston, Chicago, Columbus, Dallas, Decatur, Edinburg, GreensboroπŸ‘₯ 800 participantsπŸ“… Completion: 2028-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Parkinsons DiseaseUS 46 sites in the US

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Hoffmann-La Roche

πŸ“ Albuquerque, Amherst, Asheville, Atlantis, Birmingham, Boca Raton, Boston, BurlingtonπŸ‘₯ 900 participantsπŸ“… Completion: 2029-06
View details β†’Refer patient β†’ClinicalTrials.gov β†—
Fase 3Cancer de Colo do UteroUS 18 sites in the US

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Merck Sharp & Dohme LLC

πŸ“ Atlanta, Charlottesville, Edina, Eugene, Fort Worth, Knoxville, Las Vegas, Miami BeachπŸ‘₯ 1023 participantsπŸ“… Completion: 2031-10
View details β†’Refer patient β†’ClinicalTrials.gov β†—

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Contact us β†’